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Summary: A method is described for the rapid, economic and non-radioactive examination of DNA samples
from hypercholesterolaemic patients for familial defective apolipoprotein B-100, using a modified polymerase
chain reaction (PCR) protocol and restriction enzyme isoform genotyping. Because of the high prevalence of
familial defective apolipoprotein B-100, which is estimated to be one in 500 in most screened general
populations, interest is focussed on a simple method for detection of this point mutation. In our protocol a
diagnostic restriction site is created by PCR, using a specifically designed partly mismatched primer. In the
case of familial defective apolipoprotein B-100 the amplified DNA segment contains an additional Seal site,
whereas DNA amplified from the normal allele is resistant to Seal digestion. A rapid differentiation between
the two alleles is achieved by agarose gel electrophoresis of the Scal-digested PCR product.
Introduction
Epidemiological studies have demonstrated that ele-
vated levels of plasma cholesterol, particülarly low
density lipoprotein (LDL)1) cholesterol, are associated
with an increased risk of premature coronary heart
disease (1—3). The concentration of LDL-cholesterol
is to a large extent regulated by the interaction be-
tween apolipoprotein B^lOÖ-containhig LDL particles
and LDL receptors (4, 5). Different genetic defects in
the LDL receptor gene redüce the removal of LDL
particles via the LDL receptor pathway and lead to
the disorder of familial hypercholesterolaemia (6).
However, in some patients with primary hypercholes-
terolaemia, clearance of LDL particles from the cir-
culation is reduced, whereas the LDL receptor func-
tion is normal (7, 8). When LDL particles isolated
from these patients are used in binding studies with
normal LDL receptors of human fibroblasts, they are
found to have a markedly reduced binding activity in
comparison with normal LDL particles.
Abbreviätions: LDL, low density lipoprotein; PCR, poly-
merase chain reaction.
Apolipoprotein B-100 is the sole protein component
of LDL particles and the ligand that is recognized
and bound to the LDL receptor. To identify the defect
responsible for the reduced receptor binding, the apo-
lipoprotein B-100 gene from one proband with the
binding defect was sequenced (9). At the DNA level,
the change of a single nucleotide from G to A was
identified at position 10708 in exon 26, resulting in
the replacement of arginine by glutamine at amino
acid position 3500. In the families studied, the mutant
allele was always associated with hypercholesterolae-
mia and binding-defective LDL particles. This indi-
cated that this mutation is phenotypically inherited
in an autosomal dominant fashion. The hypercholes-
terolaemia associated with this point mutation in the
apolipoprotein B-100 gene has been designated fam-
ilial defective apolipoprotein B-100 (9).
The frequency of this disorder has been determined
in several studies (10 — 13). With the exception of a
Finnish population, where this mutation was not de-
tected, the prevalence of this disorder was one in 500
in the screened general populations. The frequency of
familial defective apolipoprotein B-100 is similar to
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classical familial hypercholesterolaeniia, making it
one of the most common single-gene mutations re-
sponsible for a clinical abnormality. A rapid assay for
examining DNA for this mutation will therefore be
very useful.
A method for detecting this point mutation using
specific oligonucleotides has been published (9). In
the described procedure, the DNA is iminobilised on
a nylon membrane after amplification by PCR1), then
hybridised with radiolabelled allele-specific oligonu-
cleotides. This hybridisation procedure is costly and
time consuming. In this report, we describe restriction
isotyping (restriction enzyme isoform genotyping) s
a simpler and faster method for the diagnosis of
familial defective apolipoprotein B-100.
Materials and Methods
Amplif icat ion of apolipoprotein B-100 sequences
from genomic DNA for restriction isotyping
Total genomic DNA was derived from white blood cells by
using a Triton X-100 iysis method (14). The reaction was started
with approximately l μg DNA in a buffer containing 10 mmol/1
Tris-HCl, pH 8.3, 50 mmol/1 KCVί.5 mmol/1 MgCl2, lg/1
gelatine, 0.25 mmol/1 of each nucleotide (BRL, Eggenstein,
F. R. G.), 66.6 nmol/1 of each primer and 2.5 units Taq-
polymerase2 (Perkin-Elmer Cetus, Langen, F. R. G.) in a total
volume of 100 μΐ The initial number of templates of a single
copy gene in l μg genomic DNA is estimated to be 3 χ l O5 (15).
Both primers were 25 n cleotides in length. The sequences of
the primers are listed in figure 1. The downstfeam primer P2
contains the two mismatches forming a pari of a Seal restriction
enzyme2) recognition site.
2) Enzymes:
Seal from Streptomyces caespitosus,
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Fig. l. New restriction polymorphism created by the point mutation at codon 3500 and modified PCR using mismatched primers.
** Mismatched nucleolides.
At the top, the sequences of the amplified DNA and the used primers are shown. The downstream primer contains the
two designed mismatches that are part of the Seal restriction enzyme recognition site. In the lower part of the figure, the
sizes of the amplified fragments and the cleaved products are demonstrated. The Seal restriction recognition site is
underlined. , *
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DNA was amplified by using the Premlll Thermocycler (B1O-
zym diagnostic, Hameln, F. R. G.). PCR was started with an
initial denaturing Step at 94 °C for 2 minutes, followed by
annealing at 55 °C for l minute and extension at 72 °C for l
minute. The next 30 cycles were performed likewise, except that
the denaturing Urne was changed to l minute.
To ascertain the success of PCR amplification, 15 μ! of the
reaction product was electrophoresed on an agarose gel (Sigma,
Deisenhofen, F. R. G.), 30 g/l, for l hour at a constant current
(100 mA).
Restriction isotyping of amplified apolipoprotein B-
100 sequcnces wi th Seal, and gel analysis
After PCR amplification, 5 units of Seal (Boehringer, Man-
nheim, F. R. G.) were added directly to 18μ1 of the reaction
mixture for digestion of the apolipoprotein B-100 sequences.
Purification of the PCR product was not necessary. The re-
sulting DNA fragments were separated in an agarose gel (Nu-
sieve 3:1; FMC BioProducts, Hameln, F. R. G.), 40 g/l, stained
with ethidium bromide. After electrophoresis, the DNA frag-
ments were visualized by UV Illumination. The size of the Seal
fragments was estimated by comparison with a molecular
weight DNA-marker (BRL, Eggenstein, F. R. G.).
L lCO
τ?* ;·>:: 3*3
Fig. 2. Blectrophoresis of SO/I-digested PCR products.
18 μΐ of the amplified DNA samples were directly di-
gested with Seal and electrophoresed on a NuSieve
agarose gel, 40 g/l. In the subjects K. R. and K. A., the
108 and 85 base pair-fragments were detected, indicating
that these individuals were heterozygous for the familial
defective apolipoprotein B-100 mutation. In K. E. and
K.W. only the 108 base pair-fragment was found, dem-
onstrating the homozygosity of the wild type allele. The
subjects are the same s those shown in figure 3.
Results
The basic experimental approach is illustrated in fig-
ure 1. In the first Step of the analysis, a 108 base pair
region of the apolipoprotein B-100 gene from position
10626 to 10733 is amplified by PCR. This region
contains the position 10708, which is crucial for fam-
ilial defective apolipoprotein B-100. The primer P2,
used for PCR amplification, is designed to obtain 2
changes in the original DNA sequence. These mis-
matched nucleotides and the nucleotide at the site of
the point mutation in apolipoprotein B-100 are part
of the recognition sequence of the Seal restriction
enzyme. The primer Pl is complementary to the nu-
cleotide sequence 10626 to 10650, and primer 2 to the
nucleotide sequence 10709 to 10733. Under the re-
action conditions used, specific amplification was ob-
served with DNA from all subjects tested.
The second step is the digestiori of the amplified DNA
fragment with Seal and subsequent agarose gel elec-
trophoresis. Amplified segments will contai the en-
zyme cleavage site only if they are derived from the
mutated locus. An 85 base pair fragnient is formed
upon cleavage with Seal (fig. 2). The PCR products
derived from the normal allele contain the introduced
ntismatched nucleotides, but lack the Seal restriction
site because of the difference at the mutated position.
In this case only the 108 base pair segment can be
detected after gel electrophoresis (fig. 2). To exclude
the possibility of false positive results, the gel was
overloaded in several instances with PCR productsjof
the normal allele after enzyme digestion, but no ad-
ditional fragments were observed.
To verify our approach, DNA from a patient with
published familial defective apolipoprotein B-100,
characterized with allele-specific oligonucleotides (pa-
tient l in reference 11) was amplified and digested
with Seal. The additional Seal cleavage site was de-
tected in the PCR product, indicating that this patient
had familial defective apolipoprotein B-100. These
results demonstrate that the sensitivity of both meth-
ods is equivalent.
With the described method, we identified other indi-
viduals with familial defective apolipoprotein B-100
(manuscript in preparation). An example of the in-
heritance of the mutation is demonstrated in figure
3. The mutation was identified in all hypercholester-
olaemic family members, while in normolipidaemic







Fig. 3. Pedigree of a family with familial defective apolipopro-
tein B-100.
LDL cholesterol (mmol/1) is given in brackeis.
The corresponding PCR products are presented in
figure 2.
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Discussion
Previous methods for the determination of familial
defective apolipoprotein B-100 were based on the use
of allele-specific oligonucleotide probes. This method
relies on the use of radioactivity and depends on
stringent hybridization and washing conditions to dis-
criminate between alleles, and it poses many technical
constraints in routine diagnostic applications. An-
other technical approach is based on the selective
amplification of the mutated allele (l 6). With a primer
complementary to the mutated sequence, amplifica-
tion of the mutated allele is possible, whereas the
primer mismatch with the wild type allele stops the
amplification process. Because of the possibility of a
non-selective amplification of the normal allele, very
stringent PCR conditions are needed. Our method
does not differentiate between the mutated and wild
type alleles during PCR, which results in reduced
susceptibility. The same base substitutions were intro-
duced into both alleles, resulting in the formation of
a restriction site only in one case.
If a new restriction site is created during PCR ampli-
fication, two strategies exist for designing a partly
mismatched primer (17—19). First, the restriction site
is present only in the amplified mutated allele or,
second, the restriction site is absent in the mutated
allele and present in the normal allele. Here we pre-
ferred the first approach, because it avoids the gen-
erating of false positive results due to incomplete
digestion. To minimize the possibility of false negative
results, we tested the efficiency of the digestion step
by parallel testing of DNA from patients known to
contain the mutation. The mutation was detected in
all these controls. In addition, even incomplete diges-
tion of the amplified DNA will result in the produc-
tion of the differentiating smaller fragment, which
indicates the high sensitivity of pur approach. False
positive results can be generated by replication errors
of the Tag DNA polymerase, if the diagnostic Seal
recognition site is created by misincorporation of nu-
cleotides into the wild-type allele. But this event is
extremely unlikely, because the number of templates
in l g genomic DNA is very large (15). Statistical
calculations to RFLP1) analysis demonstrate that if
100000 starting templates are used, the replication
errors can be neglected; however, they would dra-
matically increase if only a few templates were used
(20).
In the case of familial defective apolipoprotein B-100,
the combination of PCR, restriction enzyme digestion
and agarose gel electrophoresis offers the possibility
of screening iiidividuals in a simple and economical
way. If the method is coupled with boiling extraction
of DNA samples (21), analysis can be performed
within a day.
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